RxDoctor Payments Data

Colleen Rath, PA

Medical · York, PANPI 1164933255

Payments from drug & device makers

$535in general payments, 2019–2025

Across 30 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$154
  • AbbVie$118
  • Biohaven Pharmaceutical Holding Company Ltd.$53
  • Takeda Pharmaceuticals U.S.A., Inc.$47
  • Novo Nordisk$45
  • Biohaven Pharmaceuticals, Inc.$38
  • plus $80 from 4 others

What the payments were for

  • Food & beverage$535100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$535 in reported general payments places this provider in the 55th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$73,643
Medicare patients
187
Services billed
963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban74$82,121
JardianceEmpagliflozin31$30,713
OzempicSemaglutide26$29,557
RybelsusSemaglutide17$20,636
Breo ElliptaFluticasone/Vilanterol16$9,407
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,449
JanuviaSitagliptin Phosphate13$6,295
MyrbetriqMirabegron13$6,199
Incruse ElliptaUmeclidinium Bromide12$4,180
ShingrixVaricella-Zoster Ge/As01b/Pf12$2,672
Duloxetine Hcl84$2,336
Rosuvastatin Calcium121$2,214
Metoprolol Succinate97$1,995
Atorvastatin Calcium159$1,897
Tamsulosin Hcl66$1,689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$82,12174 claims
Novo NordiskOzempic, Rybelsus$45$50,19343 claims
MerckJanuvia$15$6,29513 claims
AbbVieSynthroid$118$1,33923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,594 medical providers in Pennsylvania.

Other medical in York

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →